• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Medivir, Cancer Research Technology collaborate to develop new class of cancer drugs

Medivir, Cancer Research Technology collaborate to develop new class of cancer drugs

April 13, 2015
CenterWatch Staff

Medivir, a research-based pharmaceutical company based in Sweden, and Cancer Research Technology (CRT), Cancer Research U.K.’s commercialization and development arm, have partnered to develop a new class of drugs that has shown promise for treating a range of different cancers, including pancreatic cancer.

CRT and Medivir will conduct a two-year research program to optimize and develop small molecules targeting the cell surface protein ADAM8, which has been linked to tumor survival, cell invasion and metastasis.

Medivir will receive an exclusive, global license to research, develop, manufacture and commercialize ADAM8 inhibitor drugs resulting from development. CRT receives an upfront payment and future success milestones as well as royalties on sales which are shared with the academic collaborators.

Blocking ADAM8 in mice with pancreatic cancer prevented the spread of the disease, shrunk tumors and significantly extended lifespan. This is thought to be due to its involvement in cell adhesion, cell migration, inflammation and the growth of blood vessels—key processes that many cancers rely on for growth and development. High levels of the protein have been linked with more aggressive tumors including those in pancreatic, breast, brain, prostate, lung, head, neck and kidney cancers.

This research will be led by Professor Jörg Bartsch as head of the TransMIT-Project Division for Research in Neuro-Oncology at TransMIT, located at Marburg University in Germany, in collaboration with Medivir. Bartsch previously worked at King’s College London where the initial patent application was filed by King’s College IP and Licensing team. Further proof-of-concept studies were funded by Cancer Research U.K. at King’s College.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing